Posterior tibial neurostimulation for faecal incontinence in community-dwelling older adults: long-term outcomes and predictors of response Authors: M. Bosch-Ramírez, L. Sánchez-Guillén, M. J. Alcaide, M. Serrano-Navidad, F. López-Rodríguez-Arias, A. Sánchez-Romero, A. Muñoz-Duyos, A. Arroyo Published: 2026 ABSTRACT BackgroundFaecal incontinence (FI) increases up to 50% with age in institutionalized older individuals, and treatment options have been scarcely studied for older people. Posterior tibial nerve stimulation (PTNS) is a minimally invasive second-line treatment available. This research aims to assess long-term clinical outcomes of PTNS using the Wexner score in community-dwelling patients aged > 65 years, and its impact on quality of life (QoL).MethodsA prospective cohort study with 61 patients (median age 71 years; 79% women) was conducted. PTNS was administered in three phases over 12 months, with follow-ups (FUs) at 3, 6, 12 and 36 months. Optimal responders (ORs) were defined as achieving a > 50% reduction in Wexner score compared with baseline. Partial responders that presented a 25–50% reduction in Wexner score were also considered as potential long-term ORs.ResultsAt the end of treatment, 64% of patients were OR, with sustained improvement in 77% of them at 36 months. Wexner score significantly decreased throughout FUs, from median ten to four (p < 0.001). Faecal incontinence quality of life questionnaires (FIQLs) showed limited improvement in depression domain at 6- and 36-month FUs. Faecal urgency improved in a logistic regression analysis (p < 0.01). Multivariable logistic regression identified increasing age as independently associated with clinical response (p = 0.04).ConclusionsPTNS was associated with improvement in incontinence severity scores and faecal urgency in selected community-dwelling older adults, although reductions in FI episode frequency and quality of life measures were limited. These findings suggest that PTNS may have a selective role within individualized management strategies, particularly in urgency-predominant symptoms.Trial registration numberNCT05016453, retrospectively registered in 2021. Introduction Faecal incontinence (FI) is defined as the incapacity to appropriately control bowel movements, resulting in uncontrolled or involuntary leakage of faeces and/or flatus for at least 3 months [1]. The prevalence of FI is estimated to increase progressively with age and institutionalization, reaching up to 50% [2]. FI leads to a high direct and indirect economic burden to the healthcare system and it is an important cause of institutionalization of older people, especially when associated with urinary incontinence (UI) [3, 4]. First-line treatment consists of symptom management by offering toileting advice, reviewing chronic medication, dietary adjustment, antidiarrheal medication and behavioural therapy with biofeedback or pelvic floor rehabilitation [5]. This is successful in 70% of patients; however, for patients that fail to achieve clinical improvement, other therapies are available [6]. Sacral nerve stimulation (SNS) represents the preferred second-line treatment by main European colorectal societies [7–9]. Although incompletely understood, its mechanism relies on providing chronic low-amplitude electrical stimulation of the S3 root, with a success rate of 54%–89% [10]. Side effects include wound infection and pain associated with battery migration [11]. Permanent treatment requires two surgical procedures, with high associated costs [12] and regular follow-up and battery changes, the latter leading to consecutive surgeries [13]. Sharing a similar mechanism of action is posterior tibial nerve stimulation (PTNS), which retrogradely stimulates the same sacral roots as SNS, but from peripheral sites in the lower limb, representing a less invasive and cheaper alternative compared with SNS, with more modest efficacy. Efficacy of PTNS has been reported between 52% and 82%, being more effective for mild FI. However, evidence is based on small observational studies [14] and four randomized clinical trials (RCT) comparing PTNS with sham stimulation [15], reporting modest results in the short-term, and none of them reporting long-term results. SNS has been studied in cognitively intact older adults, being effective for UI, but it has been scarcely studied for FI [16]. Similarly, PTNS has only been studied for UI in the older population within the electric tibial nerve stimulation to reduce incontinence in care homes (ELECTRIC) RCT [17] but has not been studied for treating FI. PTNS has been proposed as a second-line non-surgical treatment in the latest European Guidelines [8], prior to considering surgical interventions. This guideline also highlights that surgical options are less preferable for nursing home patients, but no recommendation could be made about community-dwelling patients, owing to the lack of evidence. The aims of this study were to evaluate long-term outcomes of PTNS (36 months) in elderly community-dwelling patients (> 65 years old) suffering from FI refractory to conservative treatment in order to describe outcomes for this specific population in the long-term. Secondary aims were assessing QoL of patients in terms of FIQLs and variations in faecal urgency. Methods This is a prospective interventional study with a pre-specified sub-analysis of patients aged > 65 years from a previously published cohort to assess PTNS outcomes in elderly patients with faecal incontinence. Following ethics approval (PI 66/2020), all consecutive patients treated with PTNS between 2010 and 2019 at Elche University Hospital were prospectively followed and invited to participate. The inclusion criteria comprised age > 65 years old, refractory to conservative treatment and including patients with mild-to-severe FI. Exclusion criteria were major psychological or psychiatric comorbidity, lower limb affections that would prevent from correct needle placement (i.e., diabetic ulcers, chronic wounds, extensive limb oedema) and anatomical sphincter defects requiring surgical management. Aetiological classification was heterogeneous and was not sufficiently robust to allow reliable sub-group analysis by underlying mechanism of faecal incontinence. At the beginning of the study, the patients’ medical history with current medication prescription, physical exam, anal ultrasonography and manometric data were collected. Functional independence was assessed using the Barthel Index [18] and cognitive status by Mini-Mental State Examination (MMSE) [19]. We recorded the onset of symptoms, type of incontinence, 21-day bowel habit diary [20] and number of depositions per day. The main variable in our study was Wexner Score (or Cleveland Clinic Florida Faecal Incontinence Score) [21], which is a validated severity score that combines type of incontinence and frequency of FI episodes. Quality of life (QoL) was assessed at baseline and at each follow-up by faecal incontinence quality of life questionnaire (FIQLs) [22] which is a disease-specific test for FI and measures quality of life in four domains (lifestyle, coping/behaviour, depression and embarrassment) on a scale of 1–4. Ability to delay defecation (faecal urgency) was also registered. The Likert scale [23] was used to evaluate patients’ perception of clinical improvement at the end of the study. Manometric measurement was also performed at 6- and 12-month follow-ups, recording maximal resting pressure (MRP) and maximal squeeze pressure (MSP). Clinical follow-up was assessed at 3, 6, 12 and 36 months, as detailed in Fig. 1.Fig. 1PTNS study flowchart. FU follow-up, FIQLs faecal incontinence quality of life test PTNS study flowchart. FU follow-up, FIQLs faecal incontinence quality of life test PTNS protocol (Fig. 1) PTNS sessions were performed in the out-patient clinic and these consistently lasted 30 min. Frequency of these sessions changed depending on the phase of treatment. The first phase included weekly sessions for 3 months. The second phase led to biweekly sessions for 3 more months and lastly, the third phase consisted of monthly sessions for a duration of 6 months. Assessment of the efficacy of PTNS was performed after every phase of treatment (3, 6 and 12 months) and at the end of the study (36 months). PTNS was performed by members of the Colorectal Unit, using Urgent PC stimulator device (Uroplasty, Minnetonka, MN, USA) [24]. According to our previous publication [25] patients were classified as optimal responders (OR) when they experienced a reduction of Wexner score > 50% compared with baseline; partial responders (PR) when reduction was 25–50%; and insufficient responders (IR) when reduction on Wexner score was < 25%. Optimal and partial responders passed on to successive phases of treatment, while insufficient responders were offered other therapeutic options. Statistical analysis Data analysis was performed using SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA). The quantitative results were expressed as the mean (median for the non-normally distributed data), standard deviation (SD), minimum, maximum and quartiles. The categorical variables were expressed as the number of cases and percentages. Associations between the quantitative and normally distributed variables were analysed using Student’s t-test, and Wilcoxon was performed to evaluate non-normal variables. Categorical variables were analysed using the χ2 test. Logistic regression and multivariate analysis were performed to estimate independent risk factors for optimal response to treatment as an exploratory analysis for potential predictors of response. Results are presented as odds ratios (OR) with 95% confidence intervals (CI). The statistical significance was set at p < 0.05. No correction for multiple comparisons was applied; therefore, secondary analyses should be interpreted as exploratory. Artificial intelligence tools were used to support clarity and structure. All conceptual content, interpretation of data and final editorial decisions were made entirely by the authors. Results A total of 61 community-dwelling patients (48 women, 78.7%), with a median age of 71 years (65–82), underwent PTNS for FI refractory to conservative treatment (Table 1). The median functional status by Barthel Index was 75 (45–90) and the median MMSE score was 26 (22–28). Most relevant comorbidities were concomitant UI in 31 patients (50.8%), type 2 diabetes mellitus in 21 patients (34.4%) and previous diagnosis of dementia in 14 patients (23%). Among female patients, 98% had previous obstetric history, episiotomy being the most frequent (48%), more than three vaginal deliveries (37.5%) and vaginal tear (35.4%). Anorectal ultrasound revealed no significant sphincteric abnormalities in 51% of cases.Table 1Demographic, comorbidities and anorectal characteristicsDemographicsAge71 (65–82)SexWomen48 (78.7%)Men13 (21.3%)Barthel Index75 (40–90)MMSE Score26 (22–28)ComorbiditiesType 2 diabetes mellitus21 (34.4%)Urinary incontinence31 (51%)Dementia14 (23%)Previous stroke2 (3.28%)Radicular disease8 (13%)Gastrointestinal disordersIrritable bowel syndrome (IBS)1 (1.6%)Crohn’s disease1 (1.6%)Ulcerative colitis1 (1.6%)Previous oncologic diseaseColorectal5 (8,2%)Prostatic2 (3.3%)Previous surgeryComplex pelvic surgery15 (24.6%)Sphincteroplasty1 (1.6%)Hysterectomy12 (25%)Anorectal previous comorbidityRectocele4 (6.5%)Cystocele3 (4.9%)Haemorrhoids6 (9.8%)Fistula1 (1.6%)Fissure7 (11.5%)Rectal prolapse3 (4.9%)Fibromyalgia3 (4.9%)Obstetric past historyVaginal tear17 (35.4%)Episiotomy23 (48%)Delivery with shoulder dystocia9 (18.7%)Twin delivery1 (2%)Two vaginal deliveries9 (18.7%)Three vaginal deliveries8 (16.7%) > three vaginal deliveries18 (37.5%)Sphincter morphology on UltrasoundIntact sphincters25 (51%) < 30 lesion10 (20.4%)30–90° lesion14 (28.5%)MMSE Score Mini-Mental State Examination Score Table 1Demographic, comorbidities and anorectal characteristicsDemographicsAge71 (65–82)SexWomen48 (78.7%)Men13 (21.3%)Barthel Index75 (40–90)MMSE Score26 (22–28)ComorbiditiesType 2 diabetes mellitus21 (34.4%)Urinary incontinence31 (51%)Dementia14 (23%)Previous stroke2 (3.28%)Radicular disease8 (13%)Gastrointestinal disordersIrritable bowel syndrome (IBS)1 (1.6%)Crohn’s disease1 (1.6%)Ulcerative colitis1 (1.6%)Previous oncologic diseaseColorectal5 (8,2%)Prostatic2 (3.3%)Previous surgeryComplex pelvic surgery15 (24.6%)Sphincteroplasty1 (1.6%)Hysterectomy12 (25%)Anorectal previous comorbidityRectocele4 (6.5%)Cystocele3 (4.9%)Haemorrhoids6 (9.8%)Fistula1 (1.6%)Fissure7 (11.5%)Rectal prolapse3 (4.9%)Fibromyalgia3 (4.9%)Obstetric past historyVaginal tear17 (35.4%)Episiotomy23 (48%)Delivery with shoulder dystocia9 (18.7%)Twin delivery1 (2%)Two vaginal deliveries9 (18.7%)Three vaginal deliveries8 (16.7%) > three vaginal deliveries18 (37.5%)Sphincter morphology on UltrasoundIntact sphincters25 (51%) < 30 lesion10 (20.4%)30–90° lesion14 (28.5%)MMSE Score Mini-Mental State Examination Score Demographic, comorbidities and anorectal characteristics MMSE Score Mini-Mental State Examination Score Most patients suffered from mixed FI (60%), 36% had urge FI and only 4% presented passive FI. Incontinence episodes per day at baseline were as follows: 1 episode per day (21%), 2–3 episodes per day (58%) and 4–6 episodes per day (20,7%). Time of consultation was 1–5 years since the start of symptoms in the majority of cases (41%) and 67.8% showed severe faecal urgency, not being able to delay defecation longer than a minute, and no longer than 5 min in 22.03% of patients. Baseline mean manometry measures were 25 mmHg MRP (normal value 50–90 mmHg) and 43 mmHg MSP (normal value 120–350 mmHg). The median baseline Wexner score was 10.5 (moderate). A statistically significant reduction was observed at all follow-up points (Fig. 2). By the 36-month evaluation, Wexner score showed a sustained decrease with significant differences between baseline and all follow-ups, as well as between the 3-month and both 6-month and 36-month evaluations towards mild severity (p < 0.05) (Table 2).Fig. 2Wexner score punctuation at baseline and follow-upTable 2Post hoc comparisons in Wexner scoreVisitVisitEstimateStandard errort-ValueAdj lowerAdj upperAdj PBaseline3 months2.71830.56984.771.14184.2949 < 0.0001Baseline6 months4.60660.58797.842.97976.2334 < 0.0001Baseline12 months4.64841.01050.601.85247.4444 < 0.0001Baseline36 months5.15560.61838.343.44466.8665 < 0.00013 months6 months1.88820.62863.000.14893.62750.02613 months12 months1.93001.03571.860.9357−4.79570.34233 months36 months2.43720.66183.680.60604.26850.00316 months12 months0.041811.05300.04−2.87192.95561.00006 months36 months0.54900.66960.821.3039−2.40190.924112 months36 months0.50721.04440.49−2.38283.39720.9886Bold rows highlight comparisons reaching statistical significance versus baseline (P< 0.0001). Wexner score punctuation at baseline and follow-up Table 2Post hoc comparisons in Wexner scoreVisitVisitEstimateStandard errort-ValueAdj lowerAdj upperAdj PBaseline3 months2.71830.56984.771.14184.2949 < 0.0001Baseline6 months4.60660.58797.842.97976.2334 < 0.0001Baseline12 months4.64841.01050.601.85247.4444 < 0.0001Baseline36 months5.15560.61838.343.44466.8665 < 0.00013 months6 months1.88820.62863.000.14893.62750.02613 months12 months1.93001.03571.860.9357−4.79570.34233 months36 months2.43720.66183.680.60604.26850.00316 months12 months0.041811.05300.04−2.87192.95561.00006 months36 months0.54900.66960.821.3039−2.40190.924112 months36 months0.50721.04440.49−2.38283.39720.9886Bold rows highlight comparisons reaching statistical significance versus baseline (P< 0.0001). Post hoc comparisons in Wexner score Bold rows highlight comparisons reaching statistical significance versus baseline (P< 0.0001). A decrease in the number of incontinence episodes per day was also seen at the end of the study (36-months), with no statistical difference during the study period and with 24% of patients presenting 1 FI episode per day, 57% patients with 2–3 FI episodes per day and 19% with 4–6 FI episodes per day. At the end of the 12-month treatment, 39 patients (64%) achieved OR (Fig. 3). No ORs were observed after the first phase; however, 51 patients (83.6%) achieved PR and progressed on to the second phase. After the second phase, 26 patients (42.6%) converted from PR to OR, while 16 patients remained as PR and 9 discontinued treatment owing to insufficient response (IR). During the third phase, an additional 13 patients (21.3%) converted from PR to OR. All patients that obtained OR on previous phases of treatment continued to receive PTNS sessions for up to 12 months.Fig. 3PTNS protocol flowchart. OR optimal response, PR partial response, IR insufficient response PTNS protocol flowchart. OR optimal response, PR partial response, IR insufficient response At the 36-month evaluation of patients previously exhibiting OR, 30 patients (77%) still showed OR after 2 years without any further neuromodulation treatment apart from conservative measures, maintained all along. Therefore, the global response to PTNS at the end of treatment was 64% (39 patients), descending to 49.2% (30 patients) at the end of the study (36-month follow-up). No adverse events were observed secondary to PTNS. Two patients discontinued treatment owing to bimalleolar oedema secondary to cardiac insufficiency and one patient died owing to respiratory comorbidity, both during the second phase (considered IR). Faecal urgency showed a general trend towards improvement, close to statistical significance (p = 0.059), with 67.8% of patients unable to delay defecation > 1 min at baseline, reducing to 27.2% at the end of treatment. By contrast, only 5.1% of patients could delay defecation > 10 min at baseline, which ascended to 36.3% at the final evaluation (Fig. 4), both maintained in the long-term.Fig. 4Faecal urgency Faecal urgency Logistic regression for faecal urgency showed statistically significant differences attaining reduction of number of patients unable to delay defecation up to 1 min (p = 0.0046) after PTNS. These differences were found in a post hoc analysis to happen between baseline with 6-month follow-up, OR 4.902 CI: 95% [1.099–21.739] (p = 0.0327) and between 3-month and 6-month follow-up, OR 5.5 CI: 95% [1.217–25.59] (p = 0.0205). Also, an increase in patients able to delay defecation more than 10 min (p = 0.0138) was found, when comparing baseline with 12-month follow-up, OR 0.047 CI: 95% [0.003–0.692] (p = 0.0192) and 3-month with 12-month follow-up, OR 0.048 CI: 95% [0.003–0.711] (p = 0.0207) (Table 3).Table 3Logistic regression for faecal urgency in geriatric patients treated with PTNSFaecal urgency < 1 minFaecal urgency > 10 minVisitVisitORCI 95%pORCI 95%pBaseline3 months0.8770.252–3.0480.99280.9760.90–10.5261.0000Baseline6 months4.9021.099–21.7390.03270.3010.028–3.2460.5526Baseline12 months7.5180.757–7.5180.10550.0470.003–0.6920.01923 months6 months5.5801.217–25.5980.02050.3090.029–3.3390.57073 months12 months8.5470.851–83.330.07780.0480.003–0.7110.02076 months12 months1.5380.136–17.2410.96640.1580.011–2.2120.2667Bold values denote significant odds ratios and their corresponding p-values Table 3Logistic regression for faecal urgency in geriatric patients treated with PTNSFaecal urgency < 1 minFaecal urgency > 10 minVisitVisitORCI 95%pORCI 95%pBaseline3 months0.8770.252–3.0480.99280.9760.90–10.5261.0000Baseline6 months4.9021.099–21.7390.03270.3010.028–3.2460.5526Baseline12 months7.5180.757–7.5180.10550.0470.003–0.6920.01923 months6 months5.5801.217–25.5980.02050.3090.029–3.3390.57073 months12 months8.5470.851–83.330.07780.0480.003–0.7110.02076 months12 months1.5380.136–17.2410.96640.1580.011–2.2120.2667Bold values denote significant odds ratios and their corresponding p-values Logistic regression for faecal urgency in geriatric patients treated with PTNS Bold values denote significant odds ratios and their corresponding p-values Manometric evaluations showed no statistically significant changes throughout the study (MRP: p = 0.28; MSP: p = 0.91). The FIQLs showed no significant global differences (p = 0.1675). Significant improvements were observed in the depression domain at both 6-month (p = 0.0467) and 36-month follow-ups (p = 0.0407). At the end of the study, 75.7% of patients perceived relevant clinical improvement through the Likert scale. Logistic regression was used for further analysis to determine predictors of clinical improvement after PTNS. Increasing age was the only variable independently associated with clinical improvement (p = 0.0444), with a median age of 68 years old in the group with no clinical improvement versus 72.5 years old in the group with clinical improvement. Barthel, gender, urinary incontinence and dementia did not predict clinical response (p > 0.05). These findings continued to be significant in a multivariate analysis [OR 1.311 (CI: 95% (1.007–1.7)] p = 0.0444 (Table 4).Table 4Results of multivariable logistic regression analysis on the outcome of clinical improvement in faecal incontinence in older patients treated with PTNSEffectWald chi-squarePr > ChiSqOR (CI 95%)Barthel0.17180.6785Age4.04070.04441.311 (1.007–1.708)Sex0.13530.7130Urinary incontinence0.02200.8820Dementia0.81500.3666Bold row indicates the only variable independently associated with clinical improvement (Age, p = 0.0444) Table 4Results of multivariable logistic regression analysis on the outcome of clinical improvement in faecal incontinence in older patients treated with PTNSEffectWald chi-squarePr > ChiSqOR (CI 95%)Barthel0.17180.6785Age4.04070.04441.311 (1.007–1.708)Sex0.13530.7130Urinary incontinence0.02200.8820Dementia0.81500.3666Bold row indicates the only variable independently associated with clinical improvement (Age, p = 0.0444) Results of multivariable logistic regression analysis on the outcome of clinical improvement in faecal incontinence in older patients treated with PTNS Bold row indicates the only variable independently associated with clinical improvement (Age, p = 0.0444) Owing to higher prevalence of FI in female patients and 98% of our female undergoing past obstetric history, post hoc analyses were performed in order to predict prognostic factors for response, with no statistically significant findings (p > 0.05). Discussion To our knowledge, this is the first study to evaluate long-term outcomes of PTNS exclusively in patients aged > 65 years with FI refractory to conservative treatment. Our findings suggest that PTNS was associated with clinically meaningful improvement and demonstrated a favourable safety profile in community-dwelling elderly patients, with a substantial proportion of patients maintaining clinical improvement at the final evaluation. The primary outcome of this study was reduction in Wexner score, which showed a progressive and statistically significant decrease from moderate FI to mild affliction at all follow-up intervals. At the end of treatment (12 months), 64% of patients presented OR and this response was maintained in 77% of the responder patients at the 36-month follow-up, although long-term durability of PTNS beyond this period remains uncertain. Although validated severity scoring instruments for FI such as Wexner [21], Vaizey (St. Marks) [26] and Faecal Incontinence Severity Index [27] are widely used, episodes of FI per week registered in a bowel diary has classically been the main tool used in literature to measure response to treatment, which hinders comparison of results between groups [28]. However, 64% of optimal response in Wexner Score at the end of treatment suggests that older patients with FI can achieve comparable benefits to those reported in previous broader adult PTNS cohorts. In contrast to Wexner improvement, the number of FI episodes per day did not decrease significantly during follow-up. This may be explained by the fact that PTNS better improved FI with urgency symptoms but did not significantly decrease number of incontinence episodes. Ability to delay defecation improved in a logistic regression, with a reduction in number of patients unable to delay defecation up to 1 min (p = 0.0046) and an increase in patients able to delay defecation over 10 min (p = 0.0138); which suggests that patients with mixed or urgency FI could better benefit from PTNS compared with passive FI. PNTS efficacy has been studied in four RCTs. George et al. first randomized 30 patients to transcutaneous-PTNS (T-PTNS), percutaneous-PTNS (P-PTNS) and sham stimulation [29] twice weekly for 6 weeks. Results showed benefit of PTNS over sham stimulation (p = 0.035), favouring percutaneous route. Control of faecal incontinence using distal neuromodulation (CONFIDeNT) trial [30] was a multicentre, double-blinded, pragmatic RCT that included 227 patients with FI allocated to PTNS versus sham stimulation. Although initial results for 12-week treatment did not show statistical differences between groups, a post hoc analysis [14] excluding patients with obstructive disorder syndrome did show clinical benefit of PTNS over sham stimulation (48.9% versus 18.2% response, p = 0.002; multivariable OR: 4.71; CI 1.71–12.93; p = 0.003). Van der Wilt et al. performed a single-blinded RCT, randomizing 59 patients to either PTNS or sham stimulation for 9 weeks [31] and showed small advantage of PTNS over sham stimulation (p = 0.028). Lastly, the neuromodulation for accidental bowel leakage (NOTABLe) trial [32] focused on female population and randomized patients to PTNS and sham stimulation for 12 weeks and differences were not statistically significant. All these RCTs share the same duration of treatment (12–15 weeks), according to the previous standard of treatment based on overactive bladder physiology. However, as our team [25] shared, initial rates of OR (after 12 weeks) can be limited, but these findings improved up to 64% after three phases of treatment. This could only be possible owing to the perseverance of PTNS in patients that showed initial PR (decrease between 25% and 50% of Wexner). For elderly patients, long-term efficacy (36 months) decreases progressively over time, with a 36-month efficacy of 49.2%, similar to our previous long-term results in the general population. This might leave room to study efficacy of top-up or maintenance sessions in elderly patients, as previously evaluated for global population [33]. Only one study [20] has evaluated sacral nerve stimulation (SNS) exclusively in older patients with faecal incontinence. George et al. (n = 23) reported significant long-term improvements at 44 months in weekly episodes, St Mark’s score, faecal urgency and deferral time. The permanent nature of SNS may explain its sustained efficacy and supports exploring PTNS maintenance sessions in older adults. Neither their study nor ours showed significant changes in resting or squeeze pressures, consistent with neuromodulation acting mainly on sensory afferent pathways rather than restoring structural sphincter function [34]. Whereas SNS currently retains the stronger evidence base for long-term continence outcomes, PTNS may be considered as a complementary non-surgical option in selected older adults, particularly in urgency-predominant symptoms or in patients less suitable for invasive procedures. However, PTNS requires repeated treatment sessions over time; therefore, accessibility to medical care and potential risks of repeated subcutaneous puncture might represent a relevant burden for elderly patients, although the experience of this team regarding side effects and adherence to treatment over time has been positive. FIQL scores did not show overall significant improvement; only the depression domain improved at isolated time points, so results should be interpreted cautiously. Recent randomised trials [30, 32] found no differences between PTNS and sham for FIQL or 36-item short form survey(SF-36) after 9–12 weeks. Earlier small cohorts reported QoL benefits, but FIQL complexity may limit completion in older patients. QoL perception is multifactorial; notably, 75.68% of participants rated outcomes as satisfactory on a simple Likert scale, suggesting perceived benefit despite limited changes in standardised QoL instruments. These findings suggest that the inclusion of a generic quality of life instrument, such as SF-36 or EQ-5D, may be useful in future studies to better capture patient-perceived benefit and improve comparability across interventions. The dissociation between improvements in composite severity scores and the limited changes observed in episode frequency and QoL measures suggests that statistical improvement should not necessarily be interpreted as complete restoration of continence. Interestingly, older age emerged as a positive predictor of long-term optimal response. However, this finding should be interpreted with care. The relatively small sample size may increase the risk of a small-sample effect and potential model overfitting in multivariable analysis. Furthermore, the biological plausibility of older age conferring a better neuromodulatory response remains unclear. These results should therefore be considered hypothesis-generating and require confirmation in larger, adequately powered studies. Importantly, because our cohort consisted exclusively of community-dwelling older adults with relatively preserved functional and cognitive status, these findings cannot be extrapolated to frail elderly individuals. Several limitations of this study should be acknowledged. The lack of standardised outcome measures and protocols hinders international comparisons. The lack of a younger comparison group restricts assessment of whether age itself has a meaningful impact on the response to neuromodulation. Community-dwelling, relatively fit participants limit generalizability; therefore, nursing-home and hospitalized patients would benefit from specific assessment, as Booth et al. did in care homes for UI [17]. The sample size, while adequate for statistical analysis, limits the ability to perform subgroup analyses to explore additional predictors of response. Lastly, the absence of a control group is also a significant limitation. Given that no correction for multiple comparisons was applied, secondary findings should be interpreted as exploratory. The observational design of the study precludes establishing a causal relationship between PTNS and clinical improvement. Further research is needed to confirm these findings in larger, multicentre RCT. Conclusions PTNS may represent a complementary non-surgical option for selected community-dwelling older adults, particularly in urgency-predominant symptoms, although its impact on leakage frequency and quality of life appears modest. Further randomized studies are needed to better define its role within the therapeutic algorithm, including community-dwelling and nursing-home patients.